No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Activ Surgical Joins Qualcomm Smart Cities Accelerator Program

Editor: What To Know

  • Activ Surgical, a digital surgery pioneer, today announced that it has joined the Qualcomm® Smart Cities Accelerator Program and is collaborating with Innominds on the development of next-generation surgical sensing capabilities that will usher in a new era of visibility and insights for surgeons around the world.
  • Activ Surgical and Innominds are currently working on the development of an AI-powered camera that can be used in digital surgeries, as well as a solution for big data ingestion into the cloud.
  • ActivSurgical notes as part of the Qualcomm® Advantage Network, the Qualcomm Smart Cities Accelerator Program is designed to connect cities, municipalities, government agencies and enterprises with an ecosystem of providers to help deliver greater efficiencies, cost savings, safety and sustainability.

June 30, 2020

Activ Surgical, a digital surgery pioneer, today announced that it has joined the Qualcomm® Smart Cities Accelerator Program and is collaborating with Innominds on the development of next-generation surgical sensing capabilities that will usher in a new era of visibility and insights for surgeons around the world.

ActivSurgical notes as part of the Qualcomm® Advantage Network, the Qualcomm Smart Cities Accelerator Program is designed to connect cities, municipalities, government agencies and enterprises with an ecosystem of providers to help deliver greater efficiencies, cost savings, safety and sustainability. With proven expertise in commercially deployed solutions, program members include hardware and software providers, cloud solution providers, system integrators and design and manufacturing companies, as well as those offering end-to-end smart city solutions.

“We are humbled and honored to join the Qualcomm Smart Cities Accelerator Program, particularly as we begin to ramp up deployments of our surgical intelligence platform into healthcare systems across the U.S. this year,” said Todd Usen, CEO, Activ Surgical. “We share Qualcomm Technologies’ vision to empower global access to best-in-class surgery, regardless of geography.”

Activ Surgical’s participation in the program and collaboration with Qualcomm Technologies will help increase opportunities for healthcare systems in the U.S. and in global markets to leverage its newly announced ActivEdge platform. ActivEdge is an AI and machine-learning (ML) hardware-agnostic platform that enables existing surgical systems to see in real-time what humans cannot currently see, including blood flow. Participation in the Qualcomm Smart Cities Accelerator Program will give Activ Surgical critical access to hardware- and software-enabled communication tools and 5G networks that will help bring these insights to every operating room around the world.

“Digital healthcare and telemedicine are extremely important elements of our smart, connected world, and will only continue to grow in importance,” said Sanjeet Pandit, senior director, business development and head of smart cities, Qualcomm Technologies, Inc. “We are happy to include Activ Surgical in the Qualcomm Smart Cities Accelerator Program to help grow this vital area.”

Activ Surgicals’ membership in the Qualcomm Smart Cities Accelerator Program also links it with Innominds, a specialist full-cycle product engineering services company. Activ Surgical and Innominds are currently working on the development of an AI-powered camera that can be used in digital surgeries, as well as a solution for big data ingestion into the cloud. The collaboration is expected to drive transformation initiatives in data-driven, intelligent surgery by bringing together both companies’ expertise across ML, 5G, big-data analytics and advanced visualization solutions for surgery.

“We are excited to collaborate with Innominds as part of the Qualcomm Smart Cities Accelerator Program,” said Tom Calef, CTO, Activ Surgical. “Our work will ensure that surgeons everywhere will have greater access to cutting-edge technologies that enable them to make better-informed decisions and ultimately make a greater impact on reducing the number of avoidable surgical errors that occur each day.”

“Working with Activ Surgical enables Innominds to bring together leading-edge device engineering, breakthrough software product engineering, cloud applications and AI-driven data engineering to power digital surgeries of the future,” said Anil Katakam, Chief Operating Officer, Innominds. “This collaboration will ensure that we stay at the forefront of developing AI-powered, connected camera/imaging solutions that are simpler, smarter and more cost-effective. This is a firm step in our endeavor to power the digital next initiatives of global companies that we work with.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy